CDKN2A and melanoma: Moreover, the mutation burden increases along with malignant evolution: invasive melanomas show Cyclin-Dependent Kinase inhibitor 2A (CDKN2A) loss, Phosphatase and Tensin Homolog (PTEN) loss, or TP53 mutations [51].